The Epstein-Barr virus (EBV) has been linked to autoimmune diseases like Multiple Sclerosis (MS), and there is potential in using T cell therapy to eliminate EBV and prevent future need for treatments. However, there are cost, manufacturability, and ROI issues surrounding such a large-scale treatment.